Proteomics International, inVentiv Health Collaborate on Biosimilars Development | GenomeWeb

NEW YORK (GenomeWeb News) – Proteomics International recently announced an agreement with inVentiv Health Clinical aimed at the development of biosimilars.

As part of the deal, Perth, Australia-based Proteomics International's services aimed at structural characterization and quality control testing of proposed and referenced products will be combined with inVentiv's bioanalytical capabilities.

The New Jersey-based firm provides drug development services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.